A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).
Henick B, Veluswamy R, Halmos B, Labbe K, Sender N, Sta Ana S, Chen L, Punekar S, Singh J, Lee M, Shu C, Herzberg B, Chin L, Velcheti V. A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2024, 42: tps1642-tps1642. DOI: 10.1200/jco.2024.42.16_suppl.tps1642.Peer-Reviewed Original ResearchNon-small cell lung cancerIncidence of immune-related adverse effectsImmune checkpoint inhibitorsRun-in phaseTreatment landscape of non-small cell lung cancerNon-small cell lung cancer patientsImmune checkpoint inhibitor useImmune-related adverse effectsDiagnosis of non-small cell lung cancerICI-treated patientsEarly treatment discontinuationMinority patientsCell lung cancerEarly-stage diseasePhase IV studyImprove treatment outcomesStandard of carePotential poor outcomesHealth literacy levelsReduce health disparitiesCheckpoint inhibitorsEthnic minority patientsEthnic/racial minority patientsTreatment discontinuationHealth care resources